Companies › Gliknik
2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GL-2045 IVig-like mechanism for platelet responses in ITP | – | Phase 1 | Immune Thrombocytopenia | Dec 2027 |
| GL-0719 | – | Phase 1 | First in Man Study to Evaluate Initial Safety | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05318534 | GL-0719 | Phase 1 | First in Man Study to Evaluate Initial Safety | Other | Jun 2026 |
| NCT07605845 | GL-2045 | Phase 1 | Immune Thrombocytopenia | Hematology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.